News

Three candidates that President Donald Trump is considering for FDA Commissioner are likely to speed drug approvals, analysts say.

A new report has troubling findings for payers, providers, and technology companies. Here are the key takeaways, and reactions from experts.

FDA recently granted accelerated approved for ibrutinib (Imbruvica, Janssen, Pharmacyclics), the first treatment for patients with a certain type of lymphoma.

As Donald Trump was sworn in as the 45th U.S. president, health policy experts share with Managed Healthcare Executive what’s next for healthcare.

As we begin the New Year, healthcare payers have an immediate opportunity to boost member satisfaction.

As the destiny of Obamacare takes center stage, two researchers have proposed the next-generation of HSAs-HDHPs, a new way to design health insurance plans that could win bipartisan support.

The proposed megamerger has been shot down. Find out what it means for healthcare execs.

McKesson Corp., one of the largest distributors of pharmaceuticals, agreed to pay a record civil penalty for alleged violations of the Controlled Substances Act.

Here are 3 reasons why overcoming the “fingerstick” barrier will improve patient outcomes and contribute to reductions in healthcare costs.

Care for the poor and sick is costly; someone has to pay for it.

Is the drive to value-based care really accelerating? What can be done amidst all of the uncertainty? Expert shares insights from the J.P. Morgan 35th Annual Healthcare Conference.

Decisions of the U.S. Supreme Court can have a huge impact on the healthcare industry. This year is no different.

Here are three pharmacy challenges facing healthcare executives and a two-pronged solution to help solve them.

Technology, and specifically telemedicine, has an enormous role to play in improvements to clinical work flows, care coordination, and long-term health outcomes.

FDA recently approved a long-acting opioid designed to deter abuse.

While President-elect Donald Trump recently said that the pharmaceutical industry is “getting away with murder” in terms of drug prices, the industry is trying to self-regulate before facing tighter rules from the incoming administration.

Consider these tactics that analyze and address medical errors at a system level.

Experts discuss how managed healthcare executives might benefit from the ACA repeal and other healthcare reforms.

Cancer drug costs remain the most critical challenge in care, among other things.

A repeal of key provisions of the health law could lead to significant economic disruption and substantial job losses in every state, according to a new study.

Healthcare leaders share their top book recommendations.

HHS secretary nominee Tom Price has voiced opposition to bundled payments. One expert talks about mandatory and the possibility of voluntary bundled payments.

One study shows that the way Medicare is paying for joint replacements is saving millions of dollars annually and keeping patients satisfied, too.

FDA recently expanded the use of antihemophilic factor (recombinant), pegylated (Adynovate, Shire plc) for hemophilia A patients under 12 years old.

Consumer health groups are praising Health and Human Services’ (HHS) new rule on the Medicaid 340B drug discount program, which sets a ceiling on drug prices.

Experts discuss four of the biggest concerns managed healthcare executives have about repealing the ACA.

By deploying a proactive, year-round strategy that aligns data analytics with a focused approach for addressing gaps in care, your organization can turn routine quality measurement and reporting activities into a true strategic advantage by ensuring that quality measurably improves across key metrics.

Connected devices and apps eliminating the need for manual tracking drive better long-term engagement in healthy activities, a study from Walgreens and Scripps Translational Science, shows.